Indian Markets Slide: Sensex Drops, Nifty Slips Below 25,950 Amidst Global Jitters

New Delhi, December 15, 2025: The Indian stock market kicked off the week on a weak note, extending its losing streak as key benchmark indices, the Sensex and Nifty, registered noticeable declines. Investor sentiment was dampened by a combination of global uncertainties and continued selling pressure from foreign funds.

At market close, the Sensex had fallen by approximately 260 points, indicating broad-based weakness. Similarly, the Nifty 50 slipped below the crucial psychological level of 26,000, settling in the vicinity of 25,950. The negative mood was widespread, with banking, consumer durables, and IT sectors bearing the brunt of the selling.

What’s Driving the Market Down?

Several factors contributed to the cautious and negative trading environment:

• Persistent Foreign Institutional Investor (FII) Outflows: A major overhang on the market remains the continuous selling of Indian equities by FIIs. This sustained outflow of foreign capital reduces market liquidity and signals a cautious stance towards emerging markets.
• Weak Rupee and Global Uncertainty: The Indian Rupee hit fresh lows against the US Dollar, a development that typically makes imports more expensive and fuels inflationary concerns, negatively impacting overall market sentiment. Global cues were also weak, with most Asian markets trading lower, reflecting worries over the US Federal Reserve’s policy outlook and its impact on worldwide interest rates.
• Sector-Specific Pressure: Heavyweight sectors like banking saw profit-booking and index-related adjustments, which significantly contributed to the drop in the benchmark indices.

IPO Blockbuster: Corona Remedies Lists at 38% Premium

In sharp contrast to the sluggish performance of the broader market, the shares of pharmaceutical company Corona Remedies made a spectacular debut on the bourses.

The stock listed at a premium of approximately 38% over its issue price of $1,062 per share. This strong listing was in line with high expectations generated by the stellar response to its Initial Public Offering (IPO).

Key Takeaways from Corona Remedies’ Listing:

• Strong Investor Demand: The IPO, which was an Offer for Sale (OFS) raising over ₹655 crore, was oversubscribed a massive 137 times, indicating overwhelming investor confidence in the company’s growth prospects.
• Attractive Business Fundamentals: Corona Remedies is a focused pharmaceutical firm specializing in high-growth chronic and sub-chronic therapies like women’s healthcare, cardiology, and pain management. Its low exposure to price-controlled medicines and robust financial track record (recording strong revenue and profit growth) made it an attractive investment.
• Listing Performance: The stock opened significantly higher than its issue price, showcasing the appetite for companies with sound business models and strong growth momentum, even during a broader market correction.

Market Outlook

The day’s trading clearly highlighted a two-speed market. While established stocks face pressure from global and macroeconomic factors like FII selling and currency volatility, high-quality new listings like Corona Remedies continue to demonstrate investor interest, driven by solid fundamentals and strong growth potential within the domestic economy.

Investors are advised to remain cautious, keep a close watch on global events, especially currency movements and FII flows, and focus on stocks with sound, long-term fundamentals.